ProfileGDS5678 / 1419660_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 78% 76% 78% 79% 78% 74% 80% 80% 82% 77% 78% 75% 81% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.0005176
GSM967853U87-EV human glioblastoma xenograft - Control 25.4050578
GSM967854U87-EV human glioblastoma xenograft - Control 35.0915176
GSM967855U87-EV human glioblastoma xenograft - Control 45.5730578
GSM967856U87-EV human glioblastoma xenograft - Control 55.5587879
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.2210278
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.7075774
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.5688880
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.6085680
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.9782382
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.2547977
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.474378
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.9124975
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.8365181